p53 Antibodies in the sera of patients with various types of cancer: a review.
暂无分享,去创建一个
[1] J. Marks,et al. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[2] J. Bonneterre,et al. Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer , 1995, The Lancet.
[3] S. Gansauge,et al. The role of anti-p53-autoantibodies in pancreatic disorders , 1996, International journal of pancreatology : official journal of the International Association of Pancreatology.
[4] D. Slamon,et al. Mutations of the p53 gene are not detectable in human testicular tumors. , 1994, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[5] R. Ralhan,et al. Serum p53 antibodies in patients with oral lesions: Correlation with p53/HSP70 complexes , 1997, International journal of cancer.
[6] D. Lane,et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. , 1992, Cancer research.
[7] E. Diamandis,et al. Autoantibodies against the p53 tumor suppressor gene product quantified in cancer patient serum with time-resolved immunofluorometry , 1993 .
[8] E. Paoletti,et al. p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[9] H. Zentgraf,et al. Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma. , 1996, Journal of clinical pathology.
[10] S. Ménard,et al. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] D. Pim,et al. The cellular protein p53 in human tumours. , 1984, Molecular biology & medicine.
[12] D. Lane,et al. T antigen is bound to a host protein in SY40-transformed cells , 1979, Nature.
[13] A. Yamamoto,et al. Detection of auto‐antibodies against L‐myc oncogene products in sera from lung cancer patients , 1996, International journal of cancer.
[14] T. Soussi,et al. Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. , 1994, Oncogene.
[15] T. Soussi,et al. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. , 1994, British Journal of Cancer.
[16] B. Karlan,et al. DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies. , 1996, Oncogene.
[17] J. Bourhis,et al. Analysis of p53 serum antibodies in patients with head and neck squamous cell carcinoma. , 1996, Journal of the National Cancer Institute.
[18] J. Jen,et al. A new human p53 homologue , 1998, Nature Medicine.
[19] H. Zentgraf,et al. The humoral immune response to p53 in patients with hepatocellular carcinoma is specific for malignancy and independent of the α‐fetoprotein status , 1993 .
[20] N. Peled,et al. Noninfectious Gas Accumulation in an Infarcted Spleen , 2000, Digestive Surgery.
[21] V. Rotter,et al. Abelson murine leukemia virus-induced tumors elicit antibodies against a host cell protein, P50 , 1980, Journal of virology.
[22] J. Werner,et al. p53 serum antibodies as prognostic indicator in head and neck cancer , 1997, Cancer Immunology, Immunotherapy.
[23] M Ferdeghini,et al. Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. , 1999, Gynecologic oncology.
[24] D. Pim,et al. Radioimmunoassay of the cellular protein p53 in mouse and human cell lines. , 1982, The EMBO journal.
[25] B. Milleron,et al. Prognostic significance of serum p53 antibodies in patients with limited‐stage small cell lung cancer , 2000, International journal of cancer.
[26] J. Drijfhout,et al. Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes. , 1997, Cancer letters.
[27] Lubin,et al. p53 antibodies in patients with various types of cancer: assay, identification, and characterization. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] H. Zentgraf,et al. Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study , 1999, British Journal of Cancer.
[29] J. Kovarik,et al. Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. , 1995, Oncogene.
[30] A. Yang,et al. Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers , 1997, Cell.
[31] S. Ishii,et al. Presence of circulating anti‐c‐myb oncogene product antibodies in human sera , 1991, International journal of cancer.
[32] T. Soussi,et al. Regulation of the specific DNA binding activity of Xenopus laevis p53: evidence for conserved regulation through the carboxy-terminus of the protein , 1998, Oncogene.
[33] A. Levine,et al. The SV40 A gene product is required for the production of a 54,000 MW cellular tumor antigen. , 1979, Virology.
[34] C. Brambilla,et al. Implications of p53 alterations and anti-p53 antibody response in head and neck squamous cell carcinomas. , 1998, Oral oncology.
[35] M. Hollstein,et al. Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis. , 1998, Gastroenterology.
[36] C. Harris,et al. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. , 1995, Journal of the National Cancer Institute.
[37] P. Brandt-Rauf,et al. Detection of serum p53 protein in lung cancer patients. , 1994, Journal of occupational medicine. : official publication of the Industrial Medical Association.
[38] B. Milleron,et al. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[39] W. Caspary,et al. p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. , 1996, Pancreas.
[40] E. Diamandis,et al. Circulating antibodies against p53 protein in patients with ovarian carcinoma , 1996, Cancer.
[41] P. Laurent-Puig,et al. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. , 1993, Cancer research.
[42] N. Malats,et al. Serum anti-p53 antibodies and prognosis of patients with small-cell lung cancer. , 1997, Journal of the National Cancer Institute.
[43] S. Leinster,et al. Serum p53 auto-antibodies: incidence in familial breast cancer. , 1994, European journal of cancer.
[44] M. Pfreundschuh,et al. Serological analysis of human tumor antigens: molecular definition and implications. , 1997, Molecular medicine today.
[45] K. Hemminki,et al. Serum oncoproteins in asbestosis patients. , 1995, Clinical chemistry.
[46] S. Kudo,et al. Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors , 1996, Diseases of the colon and rectum.
[47] J. Cayuela,et al. Lymphomas in patients with Sjogren's syndrome are marginal zone B-cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. , 1997, Blood.
[48] M. Fukuoka,et al. Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung. , 1997, Anticancer research.
[49] D. Thomson,et al. Analysis of the anti-p53 antibody response in cancer patients. , 1993, Cancer research.
[50] E. Diamandis,et al. p53 protein is absent from the serum of patients with lung cancer. , 1996, British Journal of Cancer.
[51] H. Bismuth,et al. Clinical significance of circulating anti-p53 antibodies in European patients with hepatocellular carcinoma , 1999, British Journal of Cancer.
[52] P. May,et al. Simian virus 40-transformed cells express new species of proteins precipitable by anti-simian virus 40 tumor serum , 1979, Journal of virology.
[53] P. Kleihues,et al. Absence of p53 gene mutations in cutaneous melanoma. , 1994, The Journal of investigative dermatology.
[54] R. Ward,et al. Antibody immunity to the HER-2/neu oncogenic protein in patients with colorectal cancer. , 1999, Human immunology.
[55] D. Thierry,et al. Detection of circulating antibodies against c-myc protein in cancer patient sera. , 1988, British Journal of Cancer.
[56] T. Soussi,et al. Multifactorial analysis of p53 alteration in human cancer: A review , 1994, International journal of cancer.
[57] J. Nikliński,et al. Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer. , 1998, Lung cancer.
[58] D. Heresbach,et al. Serum anti-p53 antibodies in patients with squamous cell carcinoma of the esophagus. , 1997, International journal of oncology.
[59] Y. Kakeji,et al. Clinical implications of serum anti‐p53 antibodies for patients with gastric carcinoma , 1999, Cancer.
[60] J. Jett,et al. Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression. , 1995, Carcinogenesis.
[61] C. Harris,et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. , 1994, Cancer research.
[62] D. Pim,et al. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer , 1982, International journal of cancer.
[63] H. Shimada,et al. Detection of Preoperative Serum Anti-p53 Antibodies in Gastric Cancer , 1999, Tumor Biology.
[64] A. Meyer,et al. Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein. , 1994, Oncogene.
[65] J. Kouyoumdjian,et al. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. , 1997, Gut.
[66] A. Larsson,et al. Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer. , 1998, British Journal of Cancer.
[67] D. Byrd,et al. Antibody to ras proteins in patients with colon cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[68] B. Wasylyk,et al. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[69] M. Osame,et al. Antibody reactivities to tumor‐suppressor protein p53 and HTLV‐I Tof, Rex and Tax in HTLV‐I‐infected people with differing clinical status , 1997, International journal of cancer.
[70] E. Diamandis,et al. Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer. , 1997, European journal of cancer.
[71] S. H. van der Burg,et al. Antibodies against p53 are associated with poor prognosis of colorectal cancer. , 1995, British Journal of Cancer.
[72] C. Bamberger,et al. A novel protein with strong homology to the tumor suppressor p53 , 1997, Oncogene.
[73] D. Carbone,et al. Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade , 1999, British Journal of Cancer.
[74] M. Arima,et al. Detection of serum p53 antibodies in patients with esophageal squamous cell carcinoma: correlation with clinicopathologic features and tumor markers. , 1998, Oncology reports.
[75] L. Crawford. The 53,000-dalton cellular protein and its role in transformation. , 1983, International review of experimental pathology.
[76] A. Schindler,et al. Detection of p53 auto-antibodies in the sera of breast cancer patients with a new recurrence using an ELISA assay. Does a correlation with the recurrence free interval exist? , 1996, European journal of gynaecological oncology.
[77] R. Perng,et al. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[78] B. Wollenberg,et al. Anti-p53 antibodies in serum of smokers and head and neck cancer patients. , 1997, Anticancer Research.
[79] R. Metcalf,et al. p53 protein accumulates frequently in early bronchial neoplasia. , 1993, Cancer research.
[80] W. Wilmanns,et al. Autoantibodies against p53 are not increased in human ascites and pleural effusions , 1996, Cancer Immunology and Immunotherapy.
[81] Thierry Soussi,et al. P53 Gene Mutation: Software and Database , 1996, Nucleic Acids Res..
[82] A. Levine,et al. Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells , 1979, Cell.
[83] R. Carroll,et al. Identification of new polypeptide species (48-55K) immunoprecipitable by antiserum to purified large T antigen and present in SV40-infected and -transformed cells. , 1979, Virology.
[84] J S Lee,et al. Clonal genetic alterations in the lungs of current and former smokers. , 1997, Journal of the National Cancer Institute.
[85] A. Neugut,et al. Levels of p53 antigen in the plasma of patients with adenomas and carcinomas of the colon. , 1995, Cancer letters.
[86] C. Harris,et al. Molecular epidemiological study of non-small-cell lung cancer from an environmentally polluted region of Poland , 1999, British Journal of Cancer.
[87] P. Jeffrey,et al. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. , 1994, Science.
[88] Jingwei Ji,et al. Retinoblastoma and p53 tumor suppressor genes in human hepatoma cell lines , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[89] S. Leinster,et al. The relationship between serum p53 autoantibodies and characteristics of human breast cancer. , 1994, British Journal of Cancer.
[90] M. Arima,et al. Detection of Serum p53 Antibodies in Mucosal Esophageal Cancer and Negative Conversion After Treatment , 1998, American Journal of Gastroenterology.
[91] A. Larsson,et al. P53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy. , 1998, Anticancer research.
[92] T. Soussi,et al. Critical residues of epitopes recognized by several anti-p53 monoclonal antibodies correspond to key residues of p53 involved in interactions with the mdm2 protein. , 2000, Journal of immunological methods.
[93] T. Soussi,et al. p53 antibodies in the saliva of patients with squamous cell carcinoma of the oral cavity , 1998, International journal of cancer.
[94] Chikashi Ishioka,et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53 , 1998, Nature Medicine.
[95] R. Zeillinger,et al. Humoral p53 antibody response is a prognostic parameter in ovarian cancer. , 1999, Anticancer research.
[96] K. Chandrasekaran,et al. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B‐cell lymphoma , 1987, International journal of cancer.
[97] H. Kawasaki,et al. Prognostic significance of serum anti-p53 antibody in patients with hepatocellular carcinoma. , 1997, Journal of hepatology.
[98] M. Montenarh,et al. Antibodies against murine double minute-2 (mdm2) in sera of patients with various gynaecological diseases. , 1995, Cancer letters.
[99] R. Sobti,et al. A study on p53 protein and anti-p53 antibodies in the sera of patients with oesophageal cancer. , 1998, Mutation research.
[100] C. Prives. Signaling to p53 Breaking the MDM2–p53 Circuit , 1998, Cell.
[101] B. Vogelstein,et al. Participation of p53 protein in the cellular response to DNA damage. , 1991, Cancer research.
[102] B. Gallie,et al. Mutations of the p53 gene do not occur in testis cancer. , 1993, Cancer research.
[103] K. Hiroshima,et al. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma , 1998, Cancer Immunology, Immunotherapy.
[104] J. Bartek,et al. Immunohtstochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies , 1993, The Journal of pathology.
[105] V. Rotter,et al. Introduction: p53 – the first twenty years , 1999, Cellular and Molecular Life Sciences CMLS.
[106] N. Rainov,et al. Absence of p53 autoantibodies in sera from glioma patients. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.
[107] E. Diamandis,et al. Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry. , 1993, Oncogene.
[108] F. Seow-Choen,et al. Mutant plasma p53 protein levels: Prognostication in colorectal carcinoma , 1997, The British journal of surgery.
[109] M. Hollstein,et al. Circulating anti-p53 antibodies in esophageal cancer patients are found predominantly in individuals with p53 core domain mutations in their tumors. , 1996, Cancer research.
[110] Yao-Tseng Chen,et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[111] E. Diamandis,et al. Humoral immune response against p53 protein in patients with colorectal carcinoma , 1997, International journal of cancer.
[112] A. Levine. p53, the Cellular Gatekeeper for Growth and Division , 1997, Cell.
[113] W. Jaschke,et al. A Comparison Between α-Fetoprotein and P53 Antibodies in the Diagnosis of Hepatocellular Carcinoma , 1998 .
[114] C. Brambilla,et al. Analysis of p53 antibody response in patients with squamous cell carcinoma of the head and neck. , 1996, Anticancer research.
[115] J. Minna,et al. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: association with improved survival. , 1993, Journal of the National Cancer Institute.
[116] T. Soussi,et al. p53 antibodies in the sera of lung cancer patients: Comparison with p53 mutation in the tumour tissue , 1995, International journal of cancer.
[117] I. Ellis,et al. The significance of p53 autoantibodies in the serum of patients with breast cancer. , 1996, Anticancer research.
[118] F. Buttitta,et al. Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer. , 1996, Anticancer Research.
[119] H. Juhl,et al. Detection of the anti-p53 antibody response in malignant and benign pancreatic disease. , 1994, British Journal of Cancer.
[120] D. Lane,et al. Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens. , 1994, Cancer research.
[121] R. Klapdor,et al. P53 auto-antibodies in the sera of patients with oral squamous cell carcinoma. , 1997, Anticancer research.
[122] J. Jett,et al. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[123] P. Laurent-Puig,et al. Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases. , 1995, Gut.
[124] J. Bartek,et al. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. , 1992, Journal of immunological methods.
[125] A. Kimchi,et al. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6 , 1991, Nature.
[126] A. Giaccia,et al. The complexity of p53 modulation: emerging patterns from divergent signals. , 1998, Genes & development.
[127] E. Appella,et al. Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[128] Thierry Soussi,et al. TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.
[129] J. Minna,et al. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. , 1992, Cancer research.
[130] I. Fidler,et al. P53 mutations are infrequent and do not correlate with the metastatic potential of human-melanoma cells. , 1993, International journal of oncology.
[131] J. Green,et al. Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation. , 1995, Cancer detection and prevention.
[132] R. Hamelin,et al. Correlations between p53‐protein accumulation, serum antibodies and gene mutation in colorectal cancer , 1999, International journal of cancer.
[133] T. Soussi,et al. Serum p53 antibodies as early markers of lung cancer , 1995, Nature Medicine.
[134] E. Diamandis,et al. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers , 1994, International journal of cancer.
[135] Iver Petersen,et al. Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system , 1993, Molecular carcinogenesis.
[136] Y. Yatabe,et al. Clinical implications of p53 autoantibodies in the sera of patients with non-small-cell lung cancer. , 1998, Journal of the National Cancer Institute.
[137] T. Soussi,et al. Very low incidence of p53 antibodies in adult non‐Hodgkin's lymphoma and multiple myeloma , 1998, British journal of haematology.